Loading...

    Explore
    • Policy Monitoring
    • Live Policy Feed
    • Billing Codes
    • NPI Medicare & Medicaid
    • Healthcare Providers
    • Health Insurance Payers
    • States
    • Service Lines
    • Taxonomy Codes
    Lookup tools
    • Billing Code Lookup
    • CPT Modifier Lookup
    • Provider Taxonomy Code Lookup
    • Healthcare Provider & Facility Lookup
    • Health Insurance Payer Lookup
    • Payer Contact Directory

    Policy & Benchmark Tools

    • Prior Authorization Lookup
    • Coverage Criteria Lookup
    • Timely Filing Lookup
    • Billing Code Reimbursement Rates
    • Payer Comparison Dashboard
    • Facility Comparison Dashboard
    • All tools

    Company

    • About OpenPayer
    • Data Sources
    • Trek Health
    OpenPayerby Trek Health
    LinkedInYouTube

    © 2026 Trek Health. All rights reserved.

    OpenPayer is built and maintained by Trek Health.

    v1.0.28
    OpenPayerBilling CodesMyeloproliferative Diseases and Disorders, Poorly Differentiated NeoplasmsDRG 837-chemotherapy-with-acute-leukemia-as-secondary-diagnosis-or-with-high-dose-chemotherapy-agent-with-mcc
    Ask Trek AI about this page

    Chemotherapy with Acute Leukemia as Secondary Diagnosis or with High Dose Chemotherapy Agent with MCC: Inpatient Reimbursement Overview

    DRG 837 addresses inpatient chemotherapy for patients with acute leukemia as a secondary diagnosis or high dose chemotherapy agents with a Major Complication or Comorbidity, defining a higher-resource case mix for hospitals. Proper classification matters because it determines Medicare payment levels that reflect increased clinical complexity, treatment intensity, and inpatient resource needs.

    Customize your policy alerts

    Sign up for drg 837 policy alerts

    Get alerted when payer policies referencing 837 are released or updated.

    Monitor payer policy activity

    Receive email alerts as soon as relevant payer policies are published or updated.

    DRG 837 Overview

    DRG 837 covers hospital inpatient cases involving chemotherapy where acute leukemia is listed as a secondary diagnosis or where a high dose chemotherapy agent is administered and a Major Complication or Comorbidity is present. This Diagnosis-Related Group captures resource intensity associated with complex chemotherapy management, higher toxicity monitoring, and complications requiring inpatient care. It matters for Medicare payment because cases classified to this DRG typically have higher relative weights and reimbursement to reflect the added clinical complexity and resource use. Accurate coding of diagnoses, procedures, and Major Complication or Comorbidity status drives correct assignment and payment under Medicare.

    Table of contents

    Progress1 / 3

    Explore openpayer tools

    • Billing CodesCPT, HCPCS, DRG & more
    • Reimbursement RatesCommercial vs. Medicare rate reports
    • ProvidersHospitals & facilities
    • PayersPlans & market footprint
    • Taxonomy CodesNUCC specialty codes
    • ModifiersCPT modifiers & usage
    • Prior AuthorizationPA policies by payer & drug
    • Timely FilingFiling deadlines by payer
    • Coverage CriteriaMedical necessity by payer
    • Payer ContactsClaims, PA & appeals contacts
    View all tools

    Clinical Trials

    • Acute inpatient chemotherapy optimization studies: trials focusing on protocols for delivering intensive induction or consolidation chemotherapy to hospitalized patients with acute leukemia as a secondary diagnosis or receiving high-dose chemotherapy agents. These studies enroll patients during the acute inpatient phase to compare dosing strategies, supportive care bundles (e.g., antimicrobial prophylaxis timing, transfusion triggers, and growth factor use), and management of immediate toxicities such as febrile neutropenia or mucositis. Results inform clinicians and hospital administrators about best practices that can reduce length of stay, prevent ICU transfers, and lower complication-driven costs relevant to DRG 837 reimbursements.
    • Comparative effectiveness and safety studies of high-dose chemotherapy regimens in medically complex patients: observational cohorts or pragmatic randomized trials evaluating different high-dose chemotherapy approaches in patients who have significant comorbidities, prior malignancies, or treatment-related organ dysfunction and who therefore qualify for this DRG. These studies measure treatments’ relative efficacy, adverse event profiles, and resource utilization (transfusion needs, inpatient days, readmissions), helping payers and providers assess which regimens yield acceptable clinical benefit while minimizing high-cost complications in a high-risk inpatient population.
    • Post-discharge outcomes and care transitions research: prospective studies examining short- and medium-term outcomes after hospital discharge following intensive chemotherapy episodes, including readmission rates, infection-related complications, outpatient supportive care needs, and patient-reported functional status. This research targets patients classified under DRG 837 to identify predictors of early readmission and to test interventions such as structured discharge planning, early outpatient follow-up, or home-based nursing support; findings are directly relevant for value-based payment models and for designing discharge pathways that reduce costly rehospitalizations.

    Related Codes

    820-LYMPHOMA-AND-LEUKEMIA-WITH-MAJOR-O-R-PROCEDURES-WITH-MCC

    Lymphoma and Leukemia with Major O.R. Procedures with MCC: Inpatient Reimbursement Overview

    821-LYMPHOMA-AND-LEUKEMIA-WITH-MAJOR-O-R-PROCEDURES-WITH-CC

    Lymphoma and Leukemia with Major O.R. Procedures with CC: Inpatient Reimbursement Overview

    822-LYMPHOMA-AND-LEUKEMIA-WITH-MAJOR-O-R-PROCEDURES-WITHOUT-CC-MCC

    Lymphoma and Leukemia with Major O.R. Procedures without CC/MCC: Inpatient Reimbursement Overview

    823-LYMPHOMA-AND-NON-ACUTE-LEUKEMIA-WITH-OTHER-PROCEDURES-WITH-MCC

    Lymphoma and Non-Acute Leukemia with Other Procedures with MCC: Inpatient Reimbursement Overview

    824-LYMPHOMA-AND-NON-ACUTE-LEUKEMIA-WITH-OTHER-PROCEDURES-WITH-CC

    Lymphoma and Non-Acute Leukemia with Other Procedures with CC: Inpatient Reimbursement Overview

    825-LYMPHOMA-AND-NON-ACUTE-LEUKEMIA-WITH-OTHER-PROCEDURES-WITHOUT-CC-MCC

    Lymphoma and Non-Acute Leukemia with Other Procedures without CC/MCC: Inpatient Reimbursement Overview

    826-MYELOPROLIFERATIVE-DISORDERS-OR-POORLY-DIFFERENTIATED-NEOPLASMS-WITH-MAJOR-O-R-PROCEDURES-WITH-MCC

    Myeloproliferative Disorders or Poorly Differentiated Neoplasms with Major O.R. Procedures with MCC: Inpatient Reimbursement Overview

    827-MYELOPROLIFERATIVE-DISORDERS-OR-POORLY-DIFFERENTIATED-NEOPLASMS-WITH-MAJOR-O-R-PROCEDURES-WITH-CC

    Myeloproliferative Disorders or Poorly Differentiated Neoplasms with Major O.R. Procedures with CC: Inpatient Reimbursement Overview

    828-MYELOPROLIFERATIVE-DISORDERS-OR-POORLY-DIFFERENTIATED-NEOPLASMS-WITH-MAJOR-O-R-PROCEDURES-WITHOUT-CC-MCC

    Myeloproliferative Disorders or Poorly Differentiated Neoplasms: Inpatient Reimbursement Overview

    829-MYELOPROLIFERATIVE-DISORDERS-OR-POORLY-DIFFERENTIATED-NEOPLASMS-WITH-OTHER-PROCEDURES-WITH-CC-MCC

    Myeloproliferative Disorders or Poorly Differentiated Neoplasms: Inpatient Reimbursement Overview

    Showing 1–10 of 27

    References

    1. 1.CPT® Codes and Descriptions. AAPC. Retrieved Aug 11, 2026.Maintains the CPT code set's official descriptions and guidelines, licensed from the American Medical Association, used as the definitional source for CPT codes on this page.
    2. 2.HCPCS Quarterly Update. Centers for Medicare & Medicaid Services (CMS). Retrieved Aug 11, 2026.CMS's quarterly release of HCPCS Level II codes and short/long descriptors, the source for HCPCS code definitions and update history.
    3. 3.ICD-10-CM Full Code List. Centers for Medicare & Medicaid Services (CMS). Retrieved Aug 11, 2026.CMS's complete ICD-10-CM diagnosis code list, used to cross-reference diagnosis codes associated with this procedure or service.
    Published by

    Trek Health powers OpenPayer with a leading commercial payer intelligence platform, seamlessly converting fragmented payer data into actionable insights for provider organizations.

    Trek Health ingests and normalizes Transparency in Coverage data and payer policy updates to give provider organizations a clear view of how commercial reimbursement behaves across markets, payers, and services. Our platform transforms raw payer disclosures into structured intelligence that supports contract evaluation, payer negotiations, and service line strategy. By combining market benchmarks with ongoing policy visibility, Trek helps teams identify variability, risk, and opportunity in commercial reimbursement. The result is faster insight, stronger negotiating positions, and more informed financial decisions.